Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bone Marrow Autograft in Limb Ischemia (BALI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00904501
Recruitment Status : Completed
First Posted : May 19, 2009
Last Update Posted : March 8, 2016
Sponsor:
Collaborator:
Etablissement Français du Sang
Information provided by (Responsible Party):
PIGNON, CHU de Reims

Brief Summary:

BALI (Bone marrow Autograft in Limb Ischemia) is a randomized double-blind trial comparing implantation of bone marrow - mononuclear cells versus placebo in patients presenting with critical leg ischemia and no surgical option.

The main end point is the survival without major amputation 6 months after implantation.

Biological studies are performed on bone marrow mononuclear cells (BM-MNC) to evaluate their angiogenic properties.


Condition or disease Intervention/treatment Phase
Peripheral Vascular Diseases Procedure: Bone marrow harvest Phase 3

Detailed Description:
One hundred and ten patients with critical leg ischemia and no surgical option will be included. A bone marrow harvest (500 mL under general anaesthesia) is performed and BM-MNC are separated and concentrated (30 mL) for all included patients. For half of them, the BM-MNC are implanted on the same day whereas the others are implanted with a placebo cell-product (30 mL saline with 4 ml peripheral blood). For these patients the BM-MNC are cryo-conserved. Only the cell therapy unit, neither the patient, nor the clinician, know whether BM-MNC or placebo is implanted. The main end point is the survival without major amputation 6 months after implantation. After this delay it is possible to use previously cryo-conserved BM-MNC. Likewise biological studies are performed on BM-MNC: flow-cytometry analysis of progenitor cells content, proteins and mRNAs expression, induced angiogenesis in animal models.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Cell Therapy in Critical Limb Ischemia
Study Start Date : March 2009
Actual Primary Completion Date : January 2015
Actual Study Completion Date : January 2015

Arm Intervention/treatment
Placebo Comparator: A
A bone marrow harvest (500 mL under general anaesthesia) is performed and BM-MNC are separated and concentrated (30mL). A placebo cell-product (30 mL saline with 4 ml peripheral blood) is implanted and the BM-MNC are cryo-conserved. Only the cell therapy unit, neither the patient, nor the clinician, know whether BM-MNC or placebo is implanted. After 6 months, it is possible to use previously cryo-conserved BM-MNC.
Procedure: Bone marrow harvest
Implantation of placebo

Experimental: B
A bone marrow harvest (500 mL under general anaesthesia) is performed and BM-MNC are separated and concentrated (30mL) . The BM-MNC are implanted on the same day. Only the cell therapy unit, neither the patient, nor the clinician, know whether BM-MNC or placebo is implanted
Procedure: Bone marrow harvest
Implantation of bone marrow - mononuclear cells




Primary Outcome Measures :
  1. Major amputation rate and mortality [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Clinical symptoms and haemodynamical parameters [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Critical limb ischemia
  • No possible surgical treatment

Exclusion Criteria:

  • Ongoing infectious disease
  • Gangrene extending beyond the digits
  • Diabetes mellitus with HbA1c > 7.5% or with proliferative retinopathy
  • History of malignant disease
  • Contra-indication to general anaesthesia
  • Chronic haemodialysis
  • Prothrombin Time < 50%
  • Recent onset (within 3 months) of myocardial infarction or brain infarction
  • Contra-indication to modification of anti-platelet or anticoagulant therapy
  • History of heparin-induced thrombocytopenia
  • Unexplained haematological abnormality

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00904501


Locations
Layout table for location information
France
CHU
Amiens, France, 80054
CHU
Besancon, France, 25030
CHU
Bordeaux, France, 33075
CHU
Bordeaux, France, 33604
CHU
Caen, France, 14033
CHU
Grenoble, France, 38043
CHU
Lille, France, 59037
CHU
Limoges, France, 87000
CHU
Marseille, France, 13005
Centre Hospitalier
Mulhouse, France, 68100
CHU
Nancy, France, 54511
CHU
Nantes, France, 44035
HEGP
Paris, France, 75908
Chu Reims
Reims, France, 51092
Chu Strasbourg
Strasbourg, France, 67091
Sponsors and Collaborators
CHU de Reims
Etablissement Français du Sang
Investigators
Layout table for investigator information
Study Director: Bernard PIGNON CHU REIMS FRANCE

Layout table for additonal information
Responsible Party: PIGNON, MD, CHU de Reims
ClinicalTrials.gov Identifier: NCT00904501    
Other Study ID Numbers: PHRC2007- N11-02
First Posted: May 19, 2009    Key Record Dates
Last Update Posted: March 8, 2016
Last Verified: March 2016
Keywords provided by PIGNON, CHU de Reims:
Limb ischemia
Cell Therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Peripheral Vascular Diseases
Peripheral Arterial Disease
Ischemia
Pathologic Processes
Cardiovascular Diseases
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases